viewSyngenta AG (ADR)

Syngenta AG unveils $6bn product pipeline to appease investors

Syngenta is working to build investor confidence in its go-it-alone strategy.

Syngenta AG (NYSE:SYT), which turned down a $4bn bid from Monsanto (NYSE:MON), said it’s speeding up the pace of innovation and has a pipeline of new technology with combined sales potential of more than $6bn.

The products include fungicides Adepidyn and Orondis that can be used on vegetables and specialty crops. 

The agrochemical supplier said it has also made progress developing hybrid wheat, a product that could go on sale by the 2020 and have annual sales of more than $3bn.

Syngenta is working to build investor confidence in its go-it-alone strategy. Management has come under increasing pressure from shareholders after it rejected Monsanto's offer which the St. Louis, Missouri-based company had valued at 470 Swiss francs ($488) a share, or roughly $46bn.

In its efforts to appease investors, Syngenta has already announced plans to sell its vegetable seeds business in the next 12 months and a $2bn share buyback.

ADRs of Syngenta climbed 0.6% to $69.79 at 10 a.m. in New York. The stock has gained 8.9% this year.

Quick facts: Syngenta AG (ADR)

Price: - -

Market: NYSE
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Lexaria Bioscience and Cannadips CEO’s discuss key point of...

Lexaria BioScience (OTC: LXRP-CSE: LXX) CEO Chris Bunka and Case Mandel, CEO of Cannadips joined Steve Darling from Proactive Vancouver on Skype with news the company has signed a licensing deal for their DehydraTech technology with Cannadips from Humboldt, California. Bunka telling Proactive...

6 hours, 11 minutes ago

2 min read